

Press Release

## TRIAGENICS, INC.

---

Contact: Leigh Colby, TriAgenics, Inc  
541.527.1800

**FOR IMMEDIATE RELEASE**  
February 18, 2025

### **TRIAGENICS ADDS 20th INTERNATIONAL PATENT TO ITS MEDICAL DEVICE PORTFOLIO**

*U.S. based oral health company further strengthens its global intellectual property position for novel 3<sup>rd</sup> molar tooth bud ablation (3TBA) technology.*

**REDMOND, Ore.** – TriAgenics, the pioneer of fully guided tooth bud ablation, has announced the grant of four additional European patents, further establishing the company’s global IP position for a novel technology designed to prevent 3<sup>rd</sup> molar formation. Germany, France, Italy, and the United Kingdom are the latest European countries to grant a patent for TriAgenics’ ablation probe system.

TriAgenics’ patented micro-ablation technology is the cornerstone behind Zero3<sup>®</sup> TBA, a preventive-care treatment for children ages 6-12. The treatment prevents the formation of 3<sup>rd</sup> molars through the application of low-level, CT-guided microwave energy. This new dental modality is based on microwave ablation techniques commonly used in the medical field. TriAgenics plans to introduce Zero3<sup>®</sup> TBA to the U.S. dental market in 2025, following clearance from the U.S. Food and Drug Administration.

Following FDA clearance, dentists will send patient CBCT and intraoral scans to TriAgenics, which will fabricate custom Zero3 kits and ship them to dentists to perform the one-minute treatment using TriAgenics’ proprietary ablation technology.

TriAgenics believes the economic impact of Zero3<sup>®</sup> TBA treatment will be massive. Total expenditures associated with extracting 3<sup>rd</sup> molars and correcting related problems is estimated to be worth nearly \$5 billion in the U.S. alone. TriAgenics estimates its total addressable market will be greater than \$2.5 billion annually when Zero3<sup>®</sup> TBA treatment becomes the new standard of care in the U.S.

---

---

#### **About TriAgenics**

TriAgenics is a disruptive oral health care company that has pioneered the development of a one-minute treatment designed to prevent 3<sup>rd</sup> molars from ever forming. Based on extensive animal trials, TriAgenics’ Zero3<sup>®</sup> TBA system is expected to eliminate all pain and complications normally associated with 3<sup>rd</sup> molar extraction. TriAgenics’ mission is to provide dentists and their patients with a non-surgical alternative that has no painful recovery or need to miss work or school. For more information, please visit [www.triagenics.com](http://www.triagenics.com).